Abstract

Introduction: Impulse control disorders (ICDs) frequently complicate dopamine agonist (DA) therapy in Parkinson's disease (PD). There is growing evidence of a high heritability for ICDs in the general population and in PD. Variants on genes belonging to the reward pathway have been shown to account for part of this heritability. We aimed to identify new pathways associated with ICDs in PD.Methods: Thirty-six Parkinsonian patients on DA therapy with (n = 18) and without ICDs (n = 18) matched on age at PD's onset, and gender was selected to represent the most extreme phenotypes of their category. Exome sequencing was performed, and variants with a strong functional impact in brain-expressed genes were selected. Allele frequencies and their distribution in genes and pathways were analyzed with single variant and SKAT-O tests. The 10 most associated variants, genes, and pathways were retained for replication in the Parkinson's progression markers initiative (PPMI) cohort.Results: None of markers tested passed the significance threshold adjusted for multiple comparisons. However, the “Adenylate cyclase activating” pathway, one of the top associated pathways in the discovery data set (p = 1.6 × 10−3) was replicated in the PPMI cohort and was significantly associated with ICDs in a post hoc pooled analysis (combined p-value 3.3 × 10−5). Two of the 10 most associated variants belonged to genes implicated in cAMP and ERK signaling (rs34193571 in RasGRF2, p = 5 × 10−4; rs1877652 in PDE2A, p = 8 × 10−4) although non-significant after Bonferroni correction.Conclusion: Our results suggest that genes implicated in the signaling pathways linked to G protein-coupled receptors participate to genetic susceptibility to ICDs in PD.

Highlights

  • Impulse control disorders (ICDs) frequently complicate dopamine agonist (DA) therapy in Parkinson’s disease (PD)

  • Our results suggest that genes implicated in the signaling pathways linked to G protein-coupled receptors participate to genetic susceptibility to ICDs in PD

  • DA doses were significantly higher in control subjects (370.3 vs. 258.7 mg/day, p = 3 × 10−4) due to the study design

Read more

Summary

Introduction

Impulse control disorders (ICDs) frequently complicate dopamine agonist (DA) therapy in Parkinson’s disease (PD). Impulse control disorders (ICDs) and related behaviors are defined by the failure to resist an impulse to perform a selfrewarding act that will cause longer-term harm to oneself or others Their prevalence is estimated between 1 and 3% in the general population while it raised up to 17% in treated Parkinsonian patients [1, 2]. The reward pathway—involving ventral areas of basal ganglia and its related cortical structures—is thought to play a central role in the pathophysiology of ICDs as suggested in several studies [16, 17] These variants explain only a small part of the phenotype’s variance, estimated to be 15–21% for pathological gambling in the general population [9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call